What is Oncolytics Biotech, Inc. Annual Net Profit?

Oncolytics Biotech, Inc. Annual Net Profit fell 14.26% in the last year to $31.71 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

What is Oncolytics Biotech, Inc. Price to Earning Ratio?

Oncolytics Biotech, Inc. Price to Earning Ratio is -2.27, which is negative.

What is Oncolytics Biotech, Inc. Stock Price?

Oncolytics Biotech, Inc. Stock Price fell 43.4% and underperformed its sector by 51.73% in the past year.

What is Oncolytics Biotech, Inc. Quarterly Net profit?

Oncolytics Biotech, Inc. Quarterly Net profit fell 103.01% YoY to $8.02 M. Its sector's average net profit growth YoY for the quarter was -41.98%.

What is Oncolytics Biotech, Inc. Debt to Equity Ratio?

Oncolytics Biotech, Inc. Debt to Equity Ratio of 0.18 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Oncolytics Biotech, Inc. Return on Equity(ROE)?

Oncolytics Biotech, Inc. Return on Equity(ROE) for the last financial year was -189.05%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Oncolytics Biotech, Inc. Mutual Fund Holding?

Oncolytics Biotech, Inc. Mutual Fund Holding decreased by 0.01% in the last quarter to 0.08.

What is Oncolytics Biotech, Inc. Institutional Holding?

Oncolytics Biotech, Inc. Institutional Holding increased by 0.01% in the last quarter to 1.42.

How is the Oncolytics Biotech, Inc. today?

The Oncolytics Biotech, Inc. today is trading in the green, up by 3.45% at 0.60.

How has Oncolytics Biotech, Inc. performed historically?

The Oncolytics Biotech, Inc. is currently trading up 3.45% on an intraday basis in the past week the index rose 1.69%. The index has been down -28.57% in the past quarter and fell -43.40% in the past year. You can view this in the overview section.

Oncolytics Biotech, Inc. XNAS: ONCY

Oncolytics Biotech, Inc. Live Share Price Today, Share Analysis and Chart

Name: Oncolytics Biotech, Inc.: Is Infosys Ltd. worth buying?
Item: Oncolytics Biotech, Inc.
Rating: 0.81050
Author: Trendlyne DVM scores

Download real time

0.60 0.02 (3.45%)

60.78% Fall from 52W High

230.1K XNAS Volume

XNAS 22 Apr, 2025 1:46 PM (EDT)

Oncolytics Biotech, Inc. Key Metrics

My Metrics

Default

Market Capitalization Below industry Median Unavailable in chosen country	52
PE TTM Negative PE TTM Unavailable in chosen country	-2.3
PEG TTM High in industry Unavailable in chosen country	0.2
Price to Book High in industry Unavailable in chosen country	17.3
Institutional holding current Qtr % Low in industry Unavailable in chosen country	1.4
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-103
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-14.3
Piotroski Score Below industry Median Unavailable in chosen country	1
Rel Perf vs Sector quarter% Unavailable in chosen country	-27.3
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-189.1
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-107.5

All financials are in CAD Million and price data in USD

Not Eligible

Expensive Valuation

1.0 / 100

Technically Bearish

31.4 / 100

No estimates available

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Oncolytics Biotech, Inc. Stock Price Analysis

Day Price Range 3.4% 1 Day return Unavailable in chosen country	0.6 (LTP) 0.60.6 LowHigh
Week Price Range 1.7% 1 Week return Unavailable in chosen country	0.6 (LTP) 0.60.6 LowHigh
Month Price Range -4.8% 1 Month return Unavailable in chosen country	0.6 (LTP) 0.50.6 LowHigh
52 Week Price Range -43.4% 1 Year return Unavailable in chosen country	0.6 (LTP) 0.51.5 LowHigh

View full Share Price History

Oncolytics Biotech, Inc. Live Price Chart

Switch to TradingView

Fetching data ...

Oncolytics Biotech, Inc. Stock Analysis

Oncolytics Biotech, Inc. stock analysis with key metrics, changes, and trends.

Oncolytics Biotech, Inc. Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$31.71 M	14.26%	negative	Annual Net Profit fell 14.26% in the last year to $31.71 M. Its sector's average net profit growth for the last fiscal year was -32.44%.
Price to Earning Ratio	-2.27	-	negative	Price to Earning Ratio is -2.27, which is negative.
Stock Price	$0.60	-43.4%	negative	Stock Price fell 43.4% and underperformed its sector by 51.73% in the past year.
Quarterly Net profit	$8.02 M	103.01%	negative	Quarterly Net profit fell 103.01% YoY to $8.02 M. Its sector's average net profit growth YoY for the quarter was -41.98%.
Debt to Equity Ratio	0.18	-	positive	Debt to Equity Ratio of 0.18 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-189.05 %	-189.05%	negative	Return on Equity(ROE) for the last financial year was -189.05%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	0.08 %	-0.01%	negative	Mutual Fund Holding decreased by 0.01% in the last quarter to 0.08.
Institutional Holding	1.42 %	0.01%	positive	Institutional Holding increased by 0.01% in the last quarter to 1.42.

VIEW LESS

Loading data..

Oncolytics Biotech, Inc. - Company Profile

What does Oncolytics Biotech, Inc. do?

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.

94.72 K

2024

Gross Remuneration

Year

Oncolytics Biotech, Inc. Live Share Price Today, Share Analysis and Chart

60.78% Fall from 52W High

Oncolytics Biotech, Inc. Key Metrics

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

Check Before You Buy

Check P/E Buy Sell Zone

Oncolytics Biotech, Inc. Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Oncolytics Biotech, Inc. Live Price Chart

Oncolytics Biotech, Inc. Stock Analysis

Oncolytics Biotech, Inc. stock analysis with key metrics, changes, and trends.

Annual Net Profit fell 14.26% in the last year to $31.71 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

Price to Earning Ratio is -2.27, which is negative.

Stock Price fell 43.4% and underperformed its sector by 51.73% in the past year.

Quarterly Net profit fell 103.01% YoY to $8.02 M. Its sector's average net profit growth YoY for the quarter was -41.98%.

Debt to Equity Ratio of 0.18 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -189.05%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding decreased by 0.01% in the last quarter to 0.08.

Institutional Holding increased by 0.01% in the last quarter to 1.42.

Oncolytics Biotech, Inc. - Company Profile

What does Oncolytics Biotech, Inc. do?

Oncolytics Biotech, Inc. Management structure

Dr. Thomas C. Heineman, M.D.

Chief Medical Officer

Dr. Matthew C. Coffey,PhD

President, Chief Executive Officer and Director

Mr. Kirk J. Look

Chief Financial Officer

Ms. Amy G. Levin

Vice President, Clinical Operations

Ms. Allison Hagerman, P. Eng.

Vice President, Product Development

Mr. Wayne Pisano

Chairman of the Board and Interim Chief Executive Officer

Oncolytics Biotech, Inc. Board of directors

Mr. Wayne Pisano

Chairman of the Board and Interim Chief Executive

Ms. Angela Holtham

Independent Director

Ms. Patricia S. Andrews

Director

Ms. Deborah M. Brown

Independent Director

Dr. Bernd R. Seizinger, M.D.,PhD

Independent Director

Mr. James T. Parsons

Independent Director

Oncolytics Biotech, Inc. FAQ

How is Oncolytics Biotech, Inc. today?

Oncolytics Biotech, Inc. today is trading in the green, and is up by 3.45% at 0.60.

How has Oncolytics Biotech, Inc. performed historically?

Oncolytics Biotech, Inc. is currently trading up 3.45% on an intraday basis. In the past week the stock rose 1.69%. stock has been down -28.57% in the past quarter and fell -43.40% in the past year. You can view this in the overview section.